MedTrace Logo

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

NCT05034536 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-05-18

No results posted yet for this study

Summary

The purpose of this research is to test the safety and effectiveness of the investigational combination of anti-Programmed Death (PD)-1 antibody therapy with or without LAG-3 inhibition (pembrolizumab or nivolumab+relatlimab) and infliximab in treating metastatic melanoma.

Conditions

Interventions

DRUG

Pembrolizumab

Intravenous infusion

DRUG

Infliximab

Intravenous infusion

DRUG

Placebo

Intravenous infusion

DRUG

Relatlimab

Intravenous infusion

DRUG

Nivolumab

Intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Ryan Sullivan, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-07
Primary Completion
2026-06-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05034536 on ClinicalTrials.gov